TY - JOUR
T1 - Erratum
T2 - First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors (Clin Cancer Res (2022) 28 (57–70) DOI: 10.1158/1078-0432.CCR-21-2160)
AU - Siu, Lillian L.
AU - Wang, Ding
AU - Hilton, John
AU - Geva, Ravit
AU - Rasco, Drew
AU - Perets, Ruth
AU - Abraham, Anson K.
AU - Wilson, Douglas C.
AU - Markensohn, Julia F.
AU - Lunceford, Jared
AU - Suttner, Leah
AU - Siddiqi, Shabana
AU - Altura, Rachel A.
AU - Maurice-Dror, Corinne
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/4/15
Y1 - 2022/4/15
N2 - In the original version of this article (1), the number of patients who had ORR to MK-4830 + pembrolizumab was correct in Table 2 (n = 8), but footnote "b"contained incorrect information regarding cancer types and the number of patients with each cancer type. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret the error.
AB - In the original version of this article (1), the number of patients who had ORR to MK-4830 + pembrolizumab was correct in Table 2 (n = 8), but footnote "b"contained incorrect information regarding cancer types and the number of patients with each cancer type. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret the error.
UR - http://www.scopus.com/inward/record.url?scp=85128274231&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-22-0564
DO - 10.1158/1078-0432.CCR-22-0564
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???
C2 - 35419588
AN - SCOPUS:85128274231
SN - 1078-0432
VL - 28
SP - 1734
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -
